ReviewTherapeutic advances in psychopharmacology2018
The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
Review in Therapeutic advances in psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants.European journal of clinical pharmacology · 2022Pooled it
- Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review.Cancer medicine · 2021Pooled it
- Cognitive-behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis.Health technology assessment (Winchester, England) · 2021Pooled it
- Acupuncture for Chronic Pain-Related Depression: A Systematic Review and Meta-Analysis.Pain research & management · 2021Pooled it
- Computational modelling and neural correlates of reinforcement learning following three-week escitalopram: a double-blind, placebo-controlled semi-randomised study.Translational psychiatry · 2025Trial
- Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
- Cannabidiol reverses depression-like behaviors by enhancing hippocampal synaptic plasticity in rats with chronic restraint stress.Veterinary world · 2025Article
- GDNF attenuates a-synuclein aggregation-induced damage to VTA-NAc dopaminergic transmission and alleviates depression-like behaviors in mice.Scientific reports · 2025Article
- Mechanistic intersections between migraine and major depressive disorder.The journal of headache and pain · 2025Review
- Exploring the neuroprotective mechanisms of Jiawei Suanzaoren decoction in depression: insights from network pharmacology and molecular docking.BMC complementary medicine and therapies · 2025Article
- Understanding social media discourse on antidepressants: unsupervised and sentiment analysis using X.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Interpretation of the pathogenesis and therapeutic mechanisms of first-episode major depressive disorder based on multiple amino acid metabolic pathways: a metabolomics study.Metabolic brain disease · 2024Article
- Selective Serotonin Reuptake Inhibitors for Cessation of Betel Quid Use in Patients with Major Depressive Disorder in Taiwan.Biomedicines · 2024Article
- 5-HT 2A and 5-HT 2C receptor antagonism differentially modulate reinforcement learning and cognitive flexibility: behavioural and computational evidence.Psychopharmacology · 2024Article
- Folate supplementation as a beneficial add-on treatment in relieving depressive symptoms: A meta-analysis of meta-analyses.Food science & nutrition · 2024Review
- Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Polypyrimidine tract binding protein knockdown reverses depression-like behaviors and cognition impairment in mice with lesioned cholinergic neurons.Frontiers in aging neuroscience · 2023Article
- Anti-Inflammatory Effect of Traditional Chinese Medicine on the Concept of Mind-Body Interface.Advances in experimental medicine and biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this review was to evaluate the efficacy of selective serotonin reuptake inhibitors (SSRIs) and SSRIs compared with other treatment modalities in preventing relapse after an episode of major depressive disorder (MDD). An Ovid MEDLINE and PsycINFO search (from 1987 to August 2017) was conducted using the following terms: selective serotonin reuptake inhibitors, antidepressants, depression, prevention, prophylaxis, relapse and MDD. Using predefined criteria, two authors independently selected and reached consensus on the included studies. Sixteen articles met the criteria: 10 compared the relapse rate of selective SSRIs with placebo or other SSRIs; one discussed the effectiveness of SSRIs plus psychotherapy, two compared SSRI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.